Eur J Cancer. 2005 Sep;41(13):2016-22.

The finasteride prostate cancer prevention trial (PCPT)--what have we learned?

Source

Department of Cancer Studies and Molecular Medicine, University of Leicester, Leicester, United Kingdom. jkm7@le.ac.uk

Abstract

In 2003, the first of two large NCI-sponsored prostate cancer chemoprevention trials was reported. The prostate cancer prevention trial (PCPT) demonstrated a 24.8% reduction in the prevalence of prostate cancer in men taking finasteride 5mg/d for 7 years. However, despite the overall reduced risk of prostate cancer, men in the finasteride-treated arm of the study were more likely to develop high-grade disease. This article examines some of the controversies aroused by the PCPT and evaluates some of the arguments that have been advanced in an attempt to explain some of the unexpected outcomes of the study. In addition, some of the recent studies assessing the potential impact of an effective chemopreventive strategy on population mortality are reviewed. To conclude, there is some discussion of factors, which need to be openly discussed with male patients who might be considered for finasteride therapy.

PMID:: 16061372; [PubMed - indexed for MEDLINE]

Publication Types, MeSH Terms, Substances

Publication Types

Review

MeSH Terms

Substances

LinkOut - more resources

Full Text Sources

Other Literature Sources

Medical

Prostate Cancer - MedlinePlus Health Information

Molecular Biology Databases

FINASTERIDE - HSDB

Supplemental Content

Related citations

Review Finasteride as a chemopreventive agent in prostate cancer: impact of the PCPT on urologic practice. [Nat Clin Pract Urol. 2006]
Review Finasteride as a chemopreventive agent in prostate cancer: impact of the PCPT on urologic practice.
Goetzl MA, Holzbeierlein JM. Nat Clin Pract Urol. 2006 Aug; 3(8):422-9.
Review Five-alpha-reductase Inhibitors for prostate cancer prevention. [Cochrane Database Syst Rev. 2008]
Review Five-alpha-reductase Inhibitors for prostate cancer prevention.
Wilt TJ, MacDonald R, Hagerty K, Schellhammer P, Kramer BS. Cochrane Database Syst Rev. 2008 Apr 16; (2):CD007091. Epub 2008 Apr 16.
[The Prostate Cancer Prevention Trial (PCPT). Relevance for clinical practice]. [Urologe A. 2007]
[The Prostate Cancer Prevention Trial (PCPT). Relevance for clinical practice].
Schmitz-Dräger BJ, Fischer C, Bismarck E, Dörsam HJ, Lümmen G. Urologe A. 2007 Oct; 46(10):1364, 1366-8, 1370.
New answers from the Prostate Cancer Prevention Trial on the chemoprevention of prostate cancer. [Arch Ital Urol Androl. 2006]
New answers from the Prostate Cancer Prevention Trial on the chemoprevention of prostate cancer.
Ankerst DP, Thompson IM. Arch Ital Urol Androl. 2006 Dec; 78(4):154-6.
Estimated impact of the Prostate Cancer Prevention Trial on population mortality. [Cancer. 2005]
Estimated impact of the Prostate Cancer Prevention Trial on population mortality.
Unger JM, Thompson IM Jr, LeBlanc M, Crowley JJ, Goodman PJ, Ford LG, Coltman CA Jr. Cancer. 2005 Apr 1; 103(7):1375-80.

See reviews... See all...

Cited by 1 PubMed Central article

Review A review of phase III clinical trials of prostate cancer chemoprevention. [Ann R Coll Surg Engl. 2007]
Review A review of phase III clinical trials of prostate cancer chemoprevention.
Thorpe JF, Jain S, Marczylo TH, Gescher AJ, Steward WP, Mellon JK. Ann R Coll Surg Engl. 2007 Apr; 89(3):207-11.

Related information

Related Citations
Calculated set of PubMed citations closely related to the selected article(s) retrieved using a word weight algorithm. Related articles are displayed in ranked order from most to least relevant, with the “linked from” citation displayed first.
Compound (MeSH Keyword)
PubChem chemical compound records that are classified under the same Medical Subject Headings (MeSH) controlled vocabulary as the current articles.
Substance (MeSH Keyword)
PubChem chemical substance (submitted) records that are classified under the same Medical Subject Headings (MeSH) controlled vocabulary as the current articles.
Cited in PMC
Full-text articles in the PubMed Central Database that cite the current articles.

Recent activity

Clear Turn Off Turn On

The finasteride prostate cancer prevention trial (PCPT)--what have we learned?
The finasteride prostate cancer prevention trial (PCPT)--what have we learned?
Eur J Cancer. 2005 Sep ;41(13):2016-22.

PubMed
Apolipoprotein E promotes the regression of atherosclerosis independently of low...
Apolipoprotein E promotes the regression of atherosclerosis independently of lowering plasma cholesterol levels.
Arterioscler Thromb Vasc Biol. 2005 Feb ;25(2):436-41. Epub 2004 Dec 9 .

PubMed
Breastfeeding during pregnancy.
Breastfeeding during pregnancy.
J Hum Lact. 1993 Jun ;9(2):83-8.

PubMed
The actin-bundling protein palladin is an Akt1-specific substrate that regulates...
The actin-bundling protein palladin is an Akt1-specific substrate that regulates breast cancer cell migration.
Mol Cell. 2010 May 14 ;38(3):333-44.

PubMed
Regulation of oxysterol-binding protein Golgi localization through protein kinas...
Regulation of oxysterol-binding protein Golgi localization through protein kinase D-mediated phosphorylation.
Mol Biol Cell. 2010 Jul 1 ;21(13):2327-37. Epub 2010 May 5 .

PubMed

Your browsing activity is empty.

Activity recording is turned off.

Turn recording back on

PubMed

Display Settings:

Send to: